A Safety Tolerance and Experimental Hyperalgesia Study of Oral NGX426 in Healthy Male Voluneteers

TorreyPines Therapeutics

Status and phase: Completed; Phase 1

Conditions: Healthy; Hyperalgesia

Treatments: Drug: Placebo; Drug: Oral NGX426 (Powder in solution)

Study type: Interventional

Funder types: Industry

Identifiers

NCT00832546

NGX426CLP1003

Details and patient eligibility

About

The purpose of this study is to determine the effects of NGX426 on intradermal capsaicin induced pain in hyperalgesia.

Enrollment: 18 patients

Sex: Male

Ages: 21 to 55 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Healthy males, age 21-55

Exclusion criteria

• Allergy to study drug

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Triple Blind

---

18 participants in 3 patient groups, including a placebo group

1

Placebo Comparator group

Description:

Placebo

Treatment:

Drug: Placebo

2

Experimental group

Description:

Powder in solution

Treatment:

Drug: Oral NGX426 (Powder in solution)

3

Experimental group

Treatment:

Drug: Oral NGX426 (Powder in solution)